Education
About Us
Working with TipRanks
Follow Us
Sera Prognostics, Inc. (SERA)
:SERA
SERA Stock Chart & Stats
$3.32
$0.42(5.34%)
At close: 4:00 PM EST
$3.32
$0.42(5.34%)
Day’s Range― - ―
52-Week Range$1.37 - $9.13
Previous CloseN/A
Volume57.63K
Average Volume (3M)37.87K
Market Cap
$118.87M
Enterprise Value$110.69M
Total Cash (Recent Filing)$43.30M
Total Debt (Recent Filing)$2.45M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Mar 25, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding37,627,033
10 Day Avg. Volume34,782
30 Day Avg. Volume37,872
Financial Highlights & Ratios
PEG Ratio0.56
Price to Book (P/B)5.65
Price to Sales (P/S)3505.16
P/FCF Ratio-18.95
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue1.17K
Enterprise Value/Gross Profit-1.88K
Enterprise Value/Ebitda-3.49
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.7
Revenue Forecast (FY)$97.00K
Bulls Say, Bears Say
Bulls Say
Commercialization OpportunityThere is significant opportunity ahead of the company with the commercialization of the PreTRM test.
Financial Position And RecommendationWith $100 million in cash expected to last through 2028, a $70 million enterprise value, and pivotal data addressing a high unmet need, the analyst reiterates a Buy recommendation.
Medicaid Pilot ProgramsSera's third-quarter update highlighted progress on Medicaid pilot programs in certain states, with Nevada signed and additional states in progress.
Bears Say
Sera Prognostics News
SERA FAQ
What was Sera Prognostics, Inc.’s price range in the past 12 months?
Sera Prognostics, Inc. lowest stock price was $1.37 and its highest was $9.13 in the past 12 months.
What is Sera Prognostics, Inc.’s market cap?
Sera Prognostics, Inc.’s market cap is $118.87M.
When is Sera Prognostics, Inc.’s upcoming earnings report date?
Sera Prognostics, Inc.’s upcoming earnings report date is Mar 25, 2026 which is in 107 days.
How were Sera Prognostics, Inc.’s earnings last quarter?
Sera Prognostics, Inc. released its earnings results on Nov 13, 2025. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.198 by $0.038.
Is Sera Prognostics, Inc. overvalued?
According to Wall Street analysts Sera Prognostics, Inc.’s price is currently Overvalued.
Does Sera Prognostics, Inc. pay dividends?
Sera Prognostics, Inc. does not currently pay dividends.
What is Sera Prognostics, Inc.’s EPS estimate?
Sera Prognostics, Inc.’s EPS estimate is -0.19.
How many shares outstanding does Sera Prognostics, Inc. have?
Sera Prognostics, Inc. has 37,627,033 shares outstanding.
What happened to Sera Prognostics, Inc.’s price movement after its last earnings report?
Sera Prognostics, Inc. reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.198. Following the earnings report the stock price went up 0.339%.
Which hedge fund is a major shareholder of Sera Prognostics, Inc.?
Currently, no hedge funds are holding shares in SERA
Sera Prognostics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Neutral
SERA Sentiment 50%
Sector Average 67%
Sector Average 67%
Insider Transactions
Sold Shares
Worth $233.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-57.80%
12-Months-Change
Fundamentals
Return on Equity
-47.69%
Trailing 12-Months
Asset Growth
36.87%
Trailing 12-Months
Company Description
Sera Prognostics, Inc.
Sera Prognostics, Inc. is a biotechnology company specializing in maternal-fetal health diagnostics. The company focuses on the development and commercialization of innovative blood tests designed to predict the risk of adverse pregnancy outcomes, such as preterm birth and other complications. Its flagship product, the SeraTest, leverages advanced proteomics to provide healthcare providers with actionable insights for better management of pregnancies, ultimately aiming to improve maternal and infant health outcomes.
SERA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant strategic progress with Medicaid pilot programs and leadership appointments, but financial metrics such as revenue decline and increased operating expenses present ongoing challenges.View all SERA earnings summariesSERA Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Ownership Overview
7.48% Insiders
3.93% Mutual Funds
31.28% Other Institutional Investors
54.41% Public Companies and
Individual Investors